Maad Rayan Publishing Company Biomedicine Advances 3080-0382 3 3 2026 07 30 Harnessing Regenerative Medicine to Improve Wound Healing Outcomes: Cellular Therapies, Biomaterials, and Nanomedicine 92 104 10.34172/bma.79 EN Mahdi Hesaraki https://orcid.org/0000-0001-7082-2446 Fatemeh Haghdoost https://orcid.org/0000-0001-6841-8698 Farhad Seif https://orcid.org/0000-0003-1275-2157 Benyamin Mashhadi https://orcid.org/0009-0004-9203-5119 Armin Nazemi Zadeh https://orcid.org/0000-0002-7083-6482 Fereshteh Sarafrazi https://orcid.org/0000-0002-2192-4777 REVIEW 10.34172/bma.79 2026 04 27 2026 07 02 Regenerative medicine examines how to use stem cells, growth factors, cellular dressings, skin substitutes, biopolymers, hydrogels, exosome-based systems, and nanoparticle-enabled delivery platforms to improve Wound Healing. It is increasingly shaping the therapeutic and conceptual approach to wound care by shifting the goal of treatment from simple wound closure to the restoration of functional tissue. This review discusses the biological rationale of wound healing. The normal process of wound healing includes several coordinated and overlapping phases of hemostasis, inflammation, proliferation, and remodeling. This sequence often is disrupted in burns, diabetic ulcers, infected wounds, and extensive traumatic injuries, which leads to chronic inflammation, delayed vascularization, defective extracellular matrix deposition, or poor epithelial regeneration. Regenerative strategies, by providing instructive cells, paracrine signals, structural scaffolds, or controlled local delivery of bioactive molecules, try to correct these failures. Regenerative medicine has seen significant advances with the development of living skin substitutes, growth factor-loaded matrices, dynamic hydrogels, electrospun nanofibers, bioprintable bioinks, and smart wound dressings. However, the variability of biomaterial composition, poor regeneration of vascular and appendages, manufacturing complexity, cost, safety concerns, and the need for standardized potency assays still limit clinical translation. A more integrated approach that combines biological signaling, scaffold design, antimicrobial control, and patient-specific wound assessment may help bridge the gap between promising experimental systems and clinically reliable regenerative wound therapies.